Table 6.
Patients on concomitant medications at the time of transplantation and at last visit
| Concomitant medication | Baseline
|
Final visit
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exon 12
|
Exon 21a
|
Exon 26
|
Exon 12
|
Exon 21a
|
Exon 26
|
|||||||
| CC (n = 54) | CT/TT (n = 93) | GG(n = 54) | GT/TT(n = 92) | CC (n = 52) | CT/TT (n = 95) | CC (n = 54) | CT/TT (n = 93) | GG (n = 54) | GT/T (n = 92) | CC (n = 52) | CT/TT (n = 95) | |
| Antihypertensive agents | ||||||||||||
| any | 38 (70.4) | 60 (64.5) | 35 (64.8) | 62 (67.4) | 34 (65.4) | 64 (67.4) | 53 (98.1) | 93 (100) | 53 (98.2) | 92 (100) | 51 (98.1) | 95 (100) |
| diuretic | 25 (46.3) | 39 (41.9) | 26 (48.2) | 38 (41.3) | 23 (44.2) | 41 (43.2) | 38 (70.4) | 68 (73.1) | 36 (66.7) | 70 (76.1) | 33 (63.5) | 73 (76.8) |
| beta blocker | 1 (1.8) | 2 (2.1) | 0 | 3 (3.3) | 0 | 3 (3.2) | 24 (44.4) | 50 (53.8) | 25 (46.3) | 48 (52.2) | 25 (48.1) | 49 (51.6) |
| calcium channel blocker | 22 (40.7) | 30 (32.3) | 18 (33.3) | 33 (35.9) | 20 (38.5) | 32 (33.7) | 53 (98.1) | 85 (91.4) | 53 (98.2) | 84 (91.3) | 51 (98.1) | 87 (91.6) |
| Nifedipine | 17 (31.5) | 18 (19.4) | 14 (25.9) | 20 (21.7) | 15 (28.8) | 20 (21.0) | 46 (85.2) | 65 (69.9)b | 45 (83.3) | 65 (70.6) | 43 (82.7) | 68 (71.6) |
| Diltiazem | 5 (9.3) | 9 (9.7) | 4 (7.4) | 10 (10.9) | 4 (7.7) | 10 (10.5) | 5 (9.3) | 11 (11.8) | 4 (7.4) | 12 (13.0) | 5 (9.6) | 11 (11.6) |
| Verapamil | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1.8) | 0 | 0 | 1 (1.1) | 0 | 1 (1.0) |
| Amlodipine | 0 | 3 (3.2) | 0 | 3 (3.3) | 1 (1.9) | 2 (2.1) | 13 (24.1) | 27 (29.0) | 15 (27.8) | 25 (27.2) | 14 (26.9) | 26 (27.4) |
| Felodipine | 0 | 0 | 0 | 0 | 0 | 0 | 3 (5.6) | 3 (3.2) | 4 (7.4) | 2 (2.2) | 4 (7.7) | 2 (2.1) |
| Lacipidine | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (1.1) | 0 | 1 (1.1) | 0 | 1 (1.0) |
| Sympatholytic agent | 5 (9.3) | 10 (10.7) | 5 (9.3) | 10 (10.9) | 3 (5.8) | 12 (12.6) | 19 (35.2) | 43 (46.2) | 17 (31.5) | 44 (47.8) | 16 (30.8) | 46 (48.4)b |
| ACE inhibitor/ARBs | 0 | 0 | 0 | 0 | 0 | 0 | 10 (18.5) | 16 (17.2) | 9 (16.7) | 16 (17.4) | 8 (15.4) | 18 (19.0) |
| Lipid-lowering agents | 0 | 0 | 0 | 0 | 0 | 0 | 10 (18.5) | 19 (20.4) | 11 (20.4) | 18 (19.6) | 11 (21.2) | 18 (19.0) |
| Antiplatelet agent | 15 (27.8) | 28 (30.1) | 15 (27.8) | 27 (29.4) | 15 (28.9) | 28 (29.5) | 38 (70.4) | 64 (68.8) | 37 (68.5) | 64 (69.6) | 35 (67.3) | 67 (70.5) |
Data are shown as number (percentage). ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blockers.
a
One patient was not characterized for exon 21.
b
P < 0.05 vs the CC/GG genotype.